Trials / Active Not Recruiting
Active Not RecruitingNCT06113445
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 467 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Povorcitinib | Oral, Tablet |
| DRUG | Placebo | Oral, Tablet |
Timeline
- Start date
- 2023-11-29
- Primary completion
- 2026-02-24
- Completion
- 2027-02-24
- First posted
- 2023-11-02
- Last updated
- 2026-03-23
Locations
100 sites across 10 countries: United States, Belgium, Canada, France, Germany, Japan, Mexico, Netherlands, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06113445. Inclusion in this directory is not an endorsement.